Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01393626
Registration number
NCT01393626
Ethics application status
Date submitted
11/07/2011
Date registered
13/07/2011
Date last updated
28/04/2017
Titles & IDs
Public title
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
Query!
Secondary ID [1]
0
0
2011-001733-16
Query!
Secondary ID [2]
0
0
A3921083
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - CP-690,550
Treatment: Drugs - CP-690,550
Placebo Comparator: Placebo BID -
Experimental: 5mg BID -
Experimental: 10mg BID -
Treatment: Drugs: Placebo
oral tablets twice daily
Treatment: Drugs: CP-690,550
oral tablets twice daily
Treatment: Drugs: CP-690,550
oral tablets twice daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants in Clinical Remission (as Defined by a Crohn's Disease Activity Index [CDAI] Score of Less Than [<] 150 Points) at Week 8
Query!
Assessment method [1]
0
0
Clinical remission was a CDAI < 150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity.
The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [1]
0
0
Week 8
Query!
Secondary outcome [1]
0
0
Percentage of Participants in Clinical Remission (CDAI <150) at Weeks 2 and 4
Query!
Assessment method [1]
0
0
Clinical remission was a CDAI <150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity.
The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [1]
0
0
Weeks 2 and 4
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Clinical Response-70 (as Defined by a Decrease in CDAI Score of at Least 70 Points From Baseline) at Weeks 2, 4, and 8
Query!
Assessment method [2]
0
0
Clinical response-70 was defined as a reduction in CDAI score from baseline of at least 70 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [2]
0
0
Baseline, Weeks 2, 4, and 8
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving Clinical Response-100 (as Defined by a Decrease in CDAI Score of at Least 100 Points From Baseline) at Weeks 2, 4, and 8
Query!
Assessment method [3]
0
0
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [3]
0
0
Baseline, Weeks 2, 4, and 8
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving Either Clinical Response-100 or Clinical Remission (CDAI<150) at Weeks 2, 4, and 8
Query!
Assessment method [4]
0
0
Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. Clinical remission was a CDAI < 150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [4]
0
0
Baseline, Weeks 2, 4, and 8
Query!
Secondary outcome [5]
0
0
CDAI Scores at Weeks 2, 4, and 8
Query!
Assessment method [5]
0
0
CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Query!
Timepoint [5]
0
0
Weeks 2, 4, and 8
Query!
Secondary outcome [6]
0
0
C-Reactive Protein (CRP) Serum Concentrations at Weeks 2, 4, and 8
Query!
Assessment method [6]
0
0
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Query!
Timepoint [6]
0
0
Weeks 2, 4, and 8
Query!
Secondary outcome [7]
0
0
Calprotectin Fecal Concentrations at Weeks 2, 4, and 8
Query!
Assessment method [7]
0
0
Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
Query!
Timepoint [7]
0
0
Weeks 2, 4, and 8
Query!
Secondary outcome [8]
0
0
Tofacitinib Plasma Concentrations From 0 to 2 Hours Post Dose on Day 1 and at Week 8/Early Termination (ET) Visit
Query!
Assessment method [8]
0
0
Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.
Query!
Timepoint [8]
0
0
Pre-dose, 20 minutes, 40 minutes, 1 hour, and 2 to 3 hours post-dose on Day 1 and Week 8/ET visit
Query!
Secondary outcome [9]
0
0
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 8/ET Visit
Query!
Assessment method [9]
0
0
The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QOL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
Query!
Timepoint [9]
0
0
Baseline, Week 8/ET visit
Query!
Secondary outcome [10]
0
0
Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 8/ET Visit Using Analysis of Covariance (ANCOVA)
Query!
Assessment method [10]
0
0
IBDQ is a validated PRO instrument for measuring QOL in IBD consisting of 32 items scored from 1 (worst response) to 7 (best response). 32 items are grouped into 4 domains scored as follows: bowel symptoms 10 - 70; systemic symptoms 5 - 35; emotional function 12 - 84; social function 5 - 35. For each domain, higher score indicates better QOL. Total score is the sum of each item score, & ranged from 32 to 224 with a higher score indicating better QOL. Positive change in total score indicated improvement in QOL.
Adjusted means were derived from an ANCOVA model with baseline value as covariate, treatment group & prior use of anti-tumor necrosis factor (TNF) alpha (a) treatments as factors.
The 15 mg BID treatment group was closed to further enrolment early in the study by Protocol Amendment 5 after only 16 participants were enrolled in this group. Therefore, the efficacy analysis was not performed for this group as the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [10]
0
0
Baseline, Week 8/ET visit
Query!
Secondary outcome [11]
0
0
Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (=) 170 at Week 8/ET Visit
Query!
Assessment method [11]
0
0
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
Query!
Timepoint [11]
0
0
Week 8/ET visit
Query!
Secondary outcome [12]
0
0
Percentage of Participants With =16 Point Increase From Baseline in IBDQ Total Score at Week 8/ET Visit
Query!
Assessment method [12]
0
0
The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QOL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QOL. Positive change in total score indicated improvement in QOL.
Query!
Timepoint [12]
0
0
Week 8/ET visit
Query!
Secondary outcome [13]
0
0
Percentage of Participants With a Response to the Patient-Reported Treatment Impact Assessment (PRTI) at Week 8/ET Visit by Category
Query!
Assessment method [13]
0
0
The IBD Patient Reported Treatment Impact Modified (PRTI) questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to re-use the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.
Query!
Timepoint [13]
0
0
Week 8/ET visit
Query!
Secondary outcome [14]
0
0
Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 8/ET Visit
Query!
Assessment method [14]
0
0
The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL.
Query!
Timepoint [14]
0
0
Baseline, Week 8/ET visit
Query!
Secondary outcome [15]
0
0
Change From Baseline SF-36 Component and Domain Scores at Week 8/ET Visit Using ANCOVA
Query!
Assessment method [15]
0
0
The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF-36 version 2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QOL.
Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group and prior use of anti-TNF alpha treatments as factors.
The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [15]
0
0
Baseline, Week 8/ET visit
Query!
Secondary outcome [16]
0
0
EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 8/ET Visit
Query!
Assessment method [16]
0
0
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from -0.594 to 1.000; a higher score indicates a better health state.
Query!
Timepoint [16]
0
0
Baseline, Week 8/ET visit
Query!
Secondary outcome [17]
0
0
Change From Baseline EQ-5D Utility Scores at Week 8/ET Visit Using ANCOVA
Query!
Assessment method [17]
0
0
EQ-5D is a participant rated questionnaire to assess health-related QoL via a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain & discomfort, anxiety & depression; 1 = better health state (no problems); 3 = worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed to a total score ranging from -0.594 to 1.000; higher score indicates better health state. Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group & prior use of anti-TNFa treatments as factors.
The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [17]
0
0
Baseline, Week 8/ET visit
Query!
Secondary outcome [18]
0
0
EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit
Query!
Assessment method [18]
0
0
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Query!
Timepoint [18]
0
0
Baseline, Week 8/ET visit
Query!
Secondary outcome [19]
0
0
Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit Using ANCOVA
Query!
Assessment method [19]
0
0
EQ-5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Adjusted means were derived from the ANCOVA model with baseline value as a covariate, treatment group & prior use of anti-TNF alpha treatments as factors.
The 15 mg BID treatment group was closed to further enrolment early on in the study by Protocol Amendment 5 after only 16 participants were enrolled into this group. Therefore, the efficacy analysis was not performed for this group because the results may be difficult to interpret due to the small sample size.
Query!
Timepoint [19]
0
0
Baseline, Week 8/ET visit
Query!
Eligibility
Key inclusion criteria
- Male or female subjects between the ages of 18 and 75 years at screening (upper age
limit will be 64 years in India and 65 years in the Netherlands).
- Subjects with clinical diagnosis of Crohn's disease for at least 6 months prior to
screening.
- Subjects with active moderate to severe ileal, ileocolic, or colonic CD defined by a
baseline score of Crohn's Disease Activity Index (CDAI) of 220 to 450 at baseline.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings
suggestive of UC.
- Subjects diagnosed with Crohn's disease but without previous exposure to treatment
(i.e., treatment-naïve).
- Subjects receiving the following treatment for Crohn's disease:
- Azathioprine, 6-mercaptopurine or methotrexate within 2 weeks prior to baseline.
- Anti-TNFa therapy within 8 weeks prior to baseline.
- Interferon therapy within 8 weeks prior to baseline.
- Cyclosporine, mycophenolate, or tacrolimus within 4 weeks prior to baseline.
- Intravenous corticosteroids within 2 weeks prior to baseline.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
280
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Nepean Public Hospital - Kingswood
Query!
Recruitment hospital [2]
0
0
Monash Medical Center - Clayton
Query!
Recruitment hospital [3]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2747 - Kingswood
Query!
Recruitment postcode(s) [2]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kansas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Hampshire
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Utah
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Virginia
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Wisconsin
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Wien
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Sofia
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Alberta
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
British Columbia
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Ontario
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Quebec
Query!
Country [28]
0
0
Croatia
Query!
State/province [28]
0
0
Rijeka
Query!
Country [29]
0
0
Croatia
Query!
State/province [29]
0
0
Zagreb
Query!
Country [30]
0
0
Czech Republic
Query!
State/province [30]
0
0
Hradec Kralove
Query!
Country [31]
0
0
Czech Republic
Query!
State/province [31]
0
0
Hradec Králové
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Lille Cedex
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Pessac
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Reims cedex
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Berlin
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Kiel
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Minden
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Ulm
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
Kolonaki Athens
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Budapest
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Gyongyos
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Kaposvar
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Szekszard
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Jerusalem
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Kfar-Saba
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Petach Tikva
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Tel Aviv
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Fukuoka
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Hokkaido
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Hyogo
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Miyagi
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Tokyo
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Chiba
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Osaka
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Seoul
Query!
Country [56]
0
0
Netherlands
Query!
State/province [56]
0
0
Amsterdam
Query!
Country [57]
0
0
South Africa
Query!
State/province [57]
0
0
Western Cape
Query!
Country [58]
0
0
South Africa
Query!
State/province [58]
0
0
Durban
Query!
Country [59]
0
0
Spain
Query!
State/province [59]
0
0
Madrid
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Barcelona
Query!
Country [61]
0
0
Ukraine
Query!
State/province [61]
0
0
Dnipropetrovsk
Query!
Country [62]
0
0
Ukraine
Query!
State/province [62]
0
0
Donetsk
Query!
Country [63]
0
0
Ukraine
Query!
State/province [63]
0
0
Kharkiv
Query!
Country [64]
0
0
Ukraine
Query!
State/province [64]
0
0
Lviv
Query!
Country [65]
0
0
Ukraine
Query!
State/province [65]
0
0
Odesa
Query!
Country [66]
0
0
Ukraine
Query!
State/province [66]
0
0
Vinnitsa
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to
severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is
more effective than placebo (inactive drug).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01393626
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01393626
Download to PDF